The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

NextCure, a US-based immuno-oncology drug developer based on research at Yale University, has secured $75m in its initial public offering. The offering consisted of 5 million shares on the Nasdaq Global Select Market priced at $15 each, in the middle of its $14 to $16 range. NextCure is working on immunomedicines that will treat diseases…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.